Profil
Christopher M.
Yea was the founder of Vantia Ltd. and held the title of Chief Operating Officer from 2008 to 2015.
Dr. Yea is currently the Chief Development Officer at KalVista Pharmaceuticals Ltd. since 2015 and at KalVista Pharmaceuticals, Inc. since 2016.
Education includes undergraduate and doctorate degrees from the University of Bristol.
Postes actifs de Christopher Yea
| Sociétés | Poste | Début |
|---|---|---|
| KALVISTA PHARMA | Corporate Officer/Principal | 01/11/2016 |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops oral medicines | Corporate Officer/Principal | 01/11/2015 |
Anciens postes connus de Christopher Yea
| Sociétés | Poste | Fin |
|---|---|---|
Vantia Ltd.
Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Provides molecule agonists of vasopressin receptors | Fondateur | 01/11/2015 |
Formation de Christopher Yea
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
University of Bristol
University of Bristol Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vantia Ltd.
Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Provides molecule agonists of vasopressin receptors | Commercial Services |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops oral medicines | Health Technology |
KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets small molecule protease inhibitors for diseases | Health Technology |
















